BlackRock Inc. trimmed its holdings in C.R. Bard, Inc. (NYSE:BCR) by 24.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,584,129 shares of the medical instruments supplier’s stock after selling 1,813,952 shares during the period. BlackRock Inc. owned approximately 7.68% of C.R. Bard worth $1,765,199,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. SRS Capital Advisors Inc. grew its stake in C.R. Bard by 0.7% in the 1st quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares in the last quarter. Alps Advisors Inc. grew its stake in C.R. Bard by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 1,921 shares of the medical instruments supplier’s stock valued at $607,000 after buying an additional 5 shares in the last quarter. KCM Investment Advisors LLC grew its stake in C.R. Bard by 0.5% in the 2nd quarter. KCM Investment Advisors LLC now owns 2,187 shares of the medical instruments supplier’s stock valued at $691,000 after buying an additional 10 shares in the last quarter. Parallel Advisors LLC grew its stake in C.R. Bard by 2.8% in the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after buying an additional 14 shares in the last quarter. Finally, Blair William & Co. IL grew its position in shares of C.R. Bard by 0.9% during the 1st quarter. Blair William & Co. IL now owns 3,492 shares of the medical instruments supplier’s stock valued at $865,000 after purchasing an additional 30 shares in the last quarter. Institutional investors and hedge funds own 79.34% of the company’s stock.

C.R. Bard, Inc. (BCR) traded down 0.29% during mid-day trading on Friday, hitting $319.57. 393,428 shares of the stock were exchanged. The company has a 50-day moving average of $320.16 and a 200-day moving average of $297.42. The stock has a market capitalization of $23.22 billion, a PE ratio of 41.95 and a beta of 0.60. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $324.58.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, topping analysts’ consensus estimates of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The business had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. During the same period last year, the company posted $2.54 EPS. The business’s revenue was up 5.2% on a year-over-year basis. On average, equities analysts predict that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “BlackRock Inc. Sells 1,813,952 Shares of C.R. Bard, Inc. (BCR)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/16/blackrock-inc-sells-1813952-shares-of-c-r-bard-inc-bcr.html.

In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of C.R. Bard stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total value of $7,549,757.51. Following the completion of the transaction, the insider now directly owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.80% of the company’s stock.

BCR has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 8th. Zacks Investment Research lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Finally, BMO Capital Markets restated a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $292.00.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.